Skip to main content
. 2022 Mar 9;45(5):1211–1218. doi: 10.2337/dc21-1138

Figure 1.

Figure 1

Distribution of life-years free of new/recurrent CVD events gained by adding semaglutide to SoC in patients with established CVD (A) and CKD only or cardiovascular risk factors only (B). *Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 (estimated using the CKD-EPI creatinine equation) and no established CVD. CV, cardiovascular.